Incretin hormone secretion (None.)

Incretin hormone secretion refers to the physiological process whereby specialized enteroendocrine cells in the gastrointestinal tract release gut-derived peptide hormones—primarily glucagon-like peptide‑1 (GLP‑1) and glucose-dependent insulinotropic polypeptide (GIP)—into circulation following nutrient ingestion. These hormones enhance glucose-stimulated insulin release from pancreatic β-cells (“the incretin effect”), regulate appetite via central nervous system pathways, slow gastric emptying, suppress glucagon production during hyperglycemia, and play roles in energy balance. While modulation of this pathway has significant therapeutic implications for type 2 diabetes mellitus and obesity through pharmacologic agents targeting GLP 1R/GIPR signaling or inhibiting DPP–4-mediated degradation, “incretin hormone secretion” itself is best understood as a biological function/process—not an individual druggable target molecule/receptor[3][5][6].

Other names

Incretin effectGut hormone secretion

For drugs targeting this pathway via its key components: Agonism at GLP‑1 or GIP receptors stimulates insulin release. DPP‑4 inhibition prolongs active incretin levels by preventing their breakdown[5]. These mechanisms do not act directly on "secretion," but modulate levels or action post-secretion.